| Signature Libraries |
2387 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2023-10 |
ASINEX's cutting edge chemistry combined with in silico and in vitro screening
validation. |
|
Macrocycle
Pre-Plated Set |
23044 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2023-10 |
ASINEX ‘s Macrocycle Pre-plated Sets are designed to provide the most popular
screening libraries in a convenient and cost-effective manner.
|
|
Diversity
Pre-Plated Set |
119877 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2023-10
|
Pre-Plated Set of compounds selected from ASINEX BioDesign Libraries, Elite
Libraries, Synergy Libraries, Gold&Platinum Collections.
|
|
Diversity-2
Pre-Plated Set |
282478 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2023-10
|
Pre-Plated Set of compounds selected from ASINEX BioDesign Libraries, Elite
Libraries, Synergy Libraries, Gold&Platinum Collections.
|
|
| PPI Pre-Plated Set |
3253 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2023-10 |
ASINEX has been working on the design and synthesis of protein-protein interaction
(PPI) libraries since 2008. The latest generation of ASINEX PPI Library comprises
molecules of various sizes, frameworks, and shapes ranging from fragment-like
entities to macrocyclic derivatives designed as secondary structure mimetics or as
epitope mimetics.
|
|
CNS Diversity
Pre-Plated Set |
6003 compounds
Pre-Plated Set
Amount: 0.01-2.0mg
Update: 2023-10 |
ASINEX has selected CNS-like molecules with high diversity:
CNS-MPO > 4
CNS-MPO.v2 > 4
CNS-TEMPO < 4
|
|
Glycomimetics
Pre-Plated Set |
2384 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2023-10 |
ASINEX has overcome these obstacles by creating a glycomimetic library that ensures
the bioactive function of carbohydrates while addressing the drawbacks of
carbohydrates, such as their low activity and poor drug-like properties.
|
|
Nucleoside-mimetics
Pre-Plated Set
|
3366 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2023-10 |
ASINEX has developed a number of stereo- and enantio-selective methods for the
synthesis of nucleoside-like core intermediates (e. g. mimics of adenosine). These
unique intermediates have been extensively decorated by various long chain amines,
acids and amino acids.
|
|
| Kinase Pre-Plated Set |
6466 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2023-10 |
ASINEX facilitates the discovery of novel kinase inhibitors by providing access to
our advanced collection of small molecules, fragments and macrocycles. The efficacy
of our compounds has been validated through in silico modeling and in vitro
on-target and phenotypic profiling. This is paralleled with 20+ years of medicinal
chemistry expertise, delivering designs with outstanding ADMET and PK properties,
optimizing chances in hit to candidate development.
|
|
Covalent Inhibitors
Pre-Plated Set
|
972 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2023-10 |
ASINEX has crafted a unique set of 1000 molecules containing electophylic moieties
that could potentially interact with cysteine residues in the target protein. The
diversity of represented scaffolds creates multiple opportunities for drug discovery
in various target and therapeutic areas such as kinases, proteases, protein-protein
interactions, and antimicrobials.
|
|
Targeted Oncology
Pre-Plated Set
|
6528 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2023-10 |
|
|
Immuno Oncology
Pre-Plated Set
|
5376 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2023-10 |
|
|
GPCR
Pre-Plated Set
|
6192 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2023-10 |
|
|
